Navigation Links
Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
Date:9/14/2007

ROCKVILLE, Md., Sept. 14 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq: NVAX) today announced that Dr. Rahul Singhvi, President and Chief Executive Officer, will present a corporate overview and highlight recent developments at the 2007 UBS Global Life Sciences Conference on Monday, September 24, 2007 at 9:30 a.m. Eastern Time at the Grand Hyatt Hotel in New York City.

A link to Dr. Singhvi's live web cast of Novavax's presentation will be available through the company's website http://www.novavax.com and will be archived on the Novavax website for 30 days.

ABOUT NOVAVAX

Novavax Inc. (Nasdaq: NVAX) is a clinical-stage vaccine company committed to leading the global fight against infectious disease by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. Novavax's particulate vaccines closely match disease-causing viruses while lacking the genetic material to cause disease, which provides potential for greater immune protection at lower doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Novavax Says Bird Flu Vaccines Effective
2. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
3. Researchers Present Ways To Reduce The Risk Of Dementia
4. Researchers Present Data Regarding The Efficiency Of Herbs
5. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
6. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
7. Drug Reactions First Present Themselves In The Mouth
8. Reminiscing Into The Past Makes You Dissatisfied With The Present
9. Living In The Past Indicates Dissatisfaction With Present
10. Movies Represent Coma In A Wrong Way
11. Onchocerciasis: Presentation And Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... , ... July 21, 2017 , ... ... received a $5,000 grant from the C. R. Bard Foundation, Inc. ... at Somerset Hills , a service available through the nonprofit home care agency. ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the first ... the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related functions ... activity levels decline over time. The study, presented today at the American ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) ... progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a ... relapse. With such a challenging diagnosis that requires immediate action, patients and ...
(Date:7/20/2017)... ... 20, 2017 , ... Team Type 1 Foundation, a nonprofit organization pursuing a ... diabetes, is teaming up with a Microsoft Corp. employee-led hackathon team for the 2017 ... , “Team Type 1’s mission overlaps seamlessly with Microsoft’s mission to empower every ...
(Date:7/20/2017)... ... 2017 , ... The Dermatology Clinic announced today the addition of Dr. Scott ... from LSU, graduating summa cum laude. He attended Emory University School of Medicine in ... Louis, Dr. Dunbar moved to New York to complete an AGCME-accredited Mohs surgery fellowship ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... Ill. , July 11, 2017  Sysmex ... and urinalysis diagnostic testing equipment as well as ... innovation: a way to make quality assurance easier ... processes. "Sysmex is well known for the innovation ... Quality Monitor elevates quality assurance processes to ...
(Date:7/11/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... (FDA) has agreed to schedule an End-of-Phase II meeting ... of its oral insulin capsule ORMD-0801 in the treatment ... primary and secondary endpoints by indicating a statistically significant ...
(Date:7/10/2017)... July 10, 2017 The Institute for In ... is the recipient of a VITROCELL® inhalation exposure system ... Science Consortium. The device, which is designed to replace ... human lung cells to airborne test materials in an ... the VITROCELL® system for testing combustible tobacco products, as ...
Breaking Medicine Technology: